 |
|
ClonazepamA Review of a New Anticonvulsant Drug
Thomas R. Browne, MD
Arch Neurol. 1976;33(5):326-332.
Abstract
• Clonazepam is a new benzodiazepine anticonvulsant recently approved by the Food and Drug Administration for the treatment of typical absence, infantile myoclonic, atypical absence, myoclonic, and akinetic seizures.
It is rapidly absorbed by the oral route and appears to pass quickly from blood to brain. Preliminary results indicate a biological half-life of 22 to 32 hours and a therapeutic serum concentration of 5 to 50 ng/ml. Many studies report tolerance to the anticonvulsant effects with chronic administration.
Major side effects of the drug are drowsiness, ataxia, and behavior changes. They tend to be dose related, occur early in the course of therapy, and may subside with chronic administration. Accordingly, the dosage is begun at a low level and increased slowly.
Author Affiliations
From the Seizure Unit and Division of Neurophysiology, Children's Hospital Medical Center, and the Department of Neurology, Harvard Medical School, Boston.
Footnotes
Accepted for publication Dec 11, 1975.
Reprint requests to Seizure Unit, Children's Hospital Medical Center, 300 Longwood Ave, Boston, MA 02115 (Dr Browne).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Benzodiazepine Withdrawal Delirium With Catatonic Features: Occurrence in Patients With Partial Seizure Disorders
Hauser et al.
Arch Neurol 1989;46:696-699.
ABSTRACT
Recent Developments in the Diagnosis and Therapy of Epilepsy
ENGEL et al.
ANN INTERN MED 1982;97:584-598.
ABSTRACT
Valproate and Clonazepam in the Treatment of Severe Progressive Myoclonus Epilepsy
Iivanainen and Himberg
Arch Neurol 1982;39:236-238.
ABSTRACT
Antimyoclonic Effect of Sodium Oxybate: Clinical Implications
Menon
JAMA 1981;245:2495-2496.
ABSTRACT
Comparative Trial of Valproate Sodium and Clonazepam in Chronic Epilepsy
Shakir et al.
Arch Neurol 1979;36:301-304.
ABSTRACT
|
